매크로라이드계 항생제 시장 규모, 점유율, 성장 및 세계 산업 분석 : 유형별, 용도별, 지역별 인사이트 및 예측(2024-2032년)

Growth Factors of macrolide antibiotics Market

The global macrolide antibiotics market continues to grow steadily as the burden of bacterial infections rises worldwide and the need for advanced antimicrobial therapies accelerates. According to the latest industry assessment, the market size reached USD 5.96 billion in 2024, driven by high prescription volumes and widespread utilization of macrolides for respiratory, skin, and sexually transmitted infections. In 2025, the market is expected to rise to USD 6.16 billion, supported by increasing demand for antibiotics with improved bioavailability and reduced microbial resistance. By 2032, the macrolide antibiotics market is projected to reach USD 8.06 billion, expanding at a CAGR of 3.9% from 2025-2032. In 2024, North America dominated the market with a 47.48% share, valued at USD 2.83 billion, attributed to strong healthcare infrastructure, high antibiotic consumption, and ongoing drug development activities.

Macrolide antibiotics function by inhibiting bacterial protein synthesis through reversible binding to the 50S ribosomal subunit. With their broad-spectrum antimicrobial capabilities, enhanced pharmacokinetics, and improved safety profile, next-generation macrolides such as azithromycin and clarithromycin continue to gain strong clinical adoption. They are especially vital in pediatric care, where alternatives such as fluoroquinolones are not recommended.

Market Drivers

A key driver of market growth is the increasing global prevalence of bacterial infections, particularly respiratory infections, sexually transmitted diseases (STIs), and skin infections. According to WHO (July 2024), 82.4 million new gonorrhea cases were reported among adults aged 15-49 years, significantly increasing demand for azithromycin and similar macrolides. Rising prescription volumes further strengthen market momentum, with U.S. retail pharmacies dispensing around 105 macrolide prescriptions per 1,000 population in 2023.

New macrolide drug reformulations are also fueling growth. The U.S. FDA approval in October 2023 for Phathom Pharmaceuticals' VOQUEZNA TRIPLE PAK and DUAL PAK for H. pylori infection has enhanced adoption of clarithromycin-inclusive treatment regimens.

Market Restraints

One of the major restraints is the growing number of product recalls linked to manufacturing defects, sterility issues, and labeling problems. Such recalls damage brand reputation and hinder consumer trust. For example, in February 2025, Singapore's Health Sciences Authority recalled Clarithromycin Eberth 500 mg due to failed sterility tests. Similarly, the U.K.'s MHRA issued multiple recalls for clarithromycin tablets in December 2023. These recurring incidents create regulatory and market-adoption challenges.

Market Opportunities

Significant opportunities are emerging across Asia, Africa, and Latin America, where bacterial infection rates remain high, and governments increasingly support indigenous drug development. A notable example includes India's launch of Nafithromycin in November 2024, developed with BIRAC support to target community-acquired bacterial pneumonia (CABP). New domestic drug launches enhance accessibility and affordability, expanding market potential in developing regions.

Regional Outlook

North America

With a market value of USD 2.83 billion in 2024, North America remains the global leader due to high disease prevalence, strong R&D initiatives, and significant investment in combating antibiotic resistance. The U.S. continues to dominate regional demand, supported by federal grants such as the USD 2.7 million NIAID funding in May 2024 for macrolide-resistance research.

Europe

Europe holds the second-largest share, driven by increased consumption of broad-spectrum antibiotics. Regional studies show a surge in antibiotic use between 2019-2021, boosting demand for macrolides used in respiratory and gastrointestinal infections.

Asia Pacific

Asia Pacific is anticipated to record the highest CAGR through 2032, supported by improving healthcare access, high disease burden, and rapid population growth. Advancements such as WHO prequalification of Bangladesh-based Rockville's azithromycin 500 mg in 2024 further strengthen regional market progress.

Latin America & Middle East/Africa

These regions show moderate but expanding demand, driven by rising bacterial infections and international collaborations. For instance, Pfizer's donation of Zithromax to WHO in June 2022 strengthens antibiotic access in trachoma-endemic nations.

Competitive Landscape

The market is semi-consolidated with leading companies such as Pfizer, Teva Pharmaceutical Industries, Merck & Co., Aurobindo Pharma, Lupin, Zydus Group, and Sun Pharma. Key strategies include generic launches, investments in R&D, and partnerships with regulatory agencies. Ongoing developments-such as Aurobindo's U.S. FDA approval for azithromycin and Alembic's clarithromycin ANDA approval-continue to shape the competitive environment.

Conclusion

Supported by rising infection rates, expanded drug development, and strong adoption across pediatric and adult populations, the macrolide antibiotics market is expected to grow from USD 5.96 billion in 2024 to USD 8.06 billion by 2032. Continuous research, international collaborations, and improved drug formulations will remain key growth accelerators throughout the forecast period.

Segmentation By Product

• Azithromycin
• Clarithromycin
• Oleandomycin
• Erythromycin
• Others

By Disease Indication

• Respiratory Infections
• Skin Infections
• Sexually Transmitted Diseases (STIs)
• Others

By Route of Administration

• Oral
• Parenteral
• Others

By Age Group

• Adults
• Pediatrics

By Distribution Channel

• Hospital Pharmacies
• Drug Stores & Retail Pharmacies
• Online Pharmacies

By Region

• North America (By Product, Disease Indication, Route of Administration, Age Group, Distribution Channel, and Country)
  • U.S.
  • Canada
• Europe (By Product, Disease Indication, Route of Administration, Age Group, Distribution Channel, and Country/sub-region)
  • Germany
  • U.K.
  • France
  • Italy
  • Spain
  • Scandinavia
  • Rest of Europe
• Asia Pacific (By Product, Disease Indication, Route of Administration, Age Group, Distribution Channel, and Country/sub-region)
  • China
  • Japan
  • India
  • Australia
  • Southeast Asia
  • Rest of Asia Pacific
• Latin America (By Product, Disease Indication, Route of Administration, Age Group, Distribution Channel, and Country/sub-region)
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East & Africa (By Product, Disease Indication, Route of Administration, Age Group, Distribution Channel, and Country/sub-region)
  • GCC
  • South Africa
  • Rest of the Middle East & Africa

Table of Content

1. Introduction

• 1.1. Research Scope
• 1.2. Market Segmentation
• 1.3. Research Methodology
• 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

• 3.1. Market Drivers
• 3.2. Market Restraints
• 3.3. Market Opportunities
• 3.4. Market Trends

4. Key Insights

• 4.1. Prevalence of Key Diseases- by Key Countries/Regions, 2024
• 4.2. Pipeline Analysis, by Key Players
• 4.3. Key Industry Developments (Mergers, Acquisitions, Partnerships, etc.)
• 4.4. Regulatory & Reimbursement Scenarios, By Key Countries/ Regions

5. Global Macrolide Antibiotics Market Analysis, Insights and Forecast, 2019-2032

• 5.1. Market Analysis, Insights and Forecast - By Product
  • 5.1.1. Azithromycin
  • 5.1.2. Clarithromycin
  • 5.1.3. Oleandomycin
  • 5.1.4. Erythromycin
  • 5.1.5. Others
• 5.2. Market Analysis, Insights and Forecast - By Disease Indication
  • 5.2.1. Respiratory Infections
  • 5.2.2. Skin Infections
  • 5.2.3. Sexually Transmitted Diseases (STIs)
  • 5.2.4. Others
• 5.3. Market Analysis, Insights and Forecast - By Route of Administration
  • 5.3.1. Oral
  • 5.3.2. Parenteral
  • 5.3.3. Others
• 5.4. Market Analysis, Insights and Forecast - By Age Group
  • 5.4.1. Adults
  • 5.4.2. Pediatrics
• 5.5. Market Analysis, Insights and Forecast - By Distribution Channel
  • 5.5.1. Hospital Pharmacies
  • 5.5.2. Drug Stores & Retail Pharmacies
  • 5.5.3. Online Pharmacies
• 5.6. Market Analysis, Insights and Forecast - Region
  • 5.6.1. North America
  • 5.6.2. Europe
  • 5.6.3. Asia Pacific
  • 5.6.4. Latin America
  • 5.6.5. Middle East & Africa

6. North America Macrolide Antibiotics Market Analysis, Insights and Forecast, 2019-2032

• 6.1. Market Analysis, Insights and Forecast - By Product
  • 6.1.1. Azithromycin
  • 6.1.2. Clarithromycin
  • 6.1.3. Oleandomycin
  • 6.1.4. Erythromycin
  • 6.1.5. Others
• 6.2. Market Analysis, Insights and Forecast - By Disease Indication
  • 6.2.1. Respiratory Infections
  • 6.2.2. Skin Infections
  • 6.2.3. Sexually Transmitted Diseases (STIs)
  • 6.2.4. Others
• 6.3. Market Analysis, Insights and Forecast - By Route of Administration
  • 6.3.1. Oral
  • 6.3.2. Parenteral
  • 6.3.3. Others
• 6.4. Market Analysis, Insights and Forecast - By Age Group
  • 6.4.1. Adults
  • 6.4.2. Pediatrics
• 6.5. Market Analysis, Insights and Forecast - By Distribution Channel
  • 6.5.1. Hospital Pharmacies
  • 6.5.2. Drug Stores & Retail Pharmacies
  • 6.5.3. Online Pharmacies
• 6.6. Market Analysis, Insights and Forecast - By Country
  • 6.6.1. U.S.
  • 6.6.2. Canada

7. Europe Macrolide Antibiotics Market Analysis, Insights and Forecast, 2019-2032

• 7.1. Market Analysis, Insights and Forecast - By Product
  • 7.1.1. Azithromycin
  • 7.1.2. Clarithromycin
  • 7.1.3. Oleandomycin
  • 7.1.4. Erythromycin
  • 7.1.5. Others
• 7.2. Market Analysis, Insights and Forecast - By Disease Indication
  • 7.2.1. Respiratory Infections
  • 7.2.2. Skin Infections
  • 7.2.3. Sexually Transmitted Diseases (STIs)
  • 7.2.4. Others
• 7.3. Market Analysis, Insights and Forecast - By Route of Administration
  • 7.3.1. Oral
  • 7.3.2. Parenteral
  • 7.3.3. Others
• 7.4. Market Analysis, Insights and Forecast - By Age Group
  • 7.4.1. Adults
  • 7.4.2. Pediatrics
• 7.5. Market Analysis, Insights and Forecast - By Distribution Channel
  • 7.5.1. Hospital Pharmacies
  • 7.5.2. Drug Stores & Retail Pharmacies
  • 7.5.3. Online Pharmacies
• 7.6. Market Analysis, Insights and Forecast - By Country/ Sub-Region
  • 7.6.1. Germany
  • 7.6.2. U.K.
  • 7.6.3. France
  • 7.6.4. Italy
  • 7.6.5. Spain
  • 7.6.6. Scandinavia
  • 7.6.7. Rest of Europe

8. Asia Pacific Macrolide Antibiotics Market Analysis, Insights and Forecast, 2019-2032

• 8.1. Market Analysis, Insights and Forecast - By Product
  • 8.1.1. Azithromycin
  • 8.1.2. Clarithromycin
  • 8.1.3. Oleandomycin
  • 8.1.4. Erythromycin
  • 8.1.5. Others
• 8.2. Market Analysis, Insights and Forecast - By Disease Indication
  • 8.2.1. Respiratory Infections
  • 8.2.2. Skin Infections
  • 8.2.3. Sexually Transmitted Diseases (STIs)
  • 8.2.4. Others
• 8.3. Market Analysis, Insights and Forecast - By Route of Administration
  • 8.3.1. Oral
  • 8.3.2. Parenteral
  • 8.3.3. Others
• 8.4. Market Analysis, Insights and Forecast - By Age Group
  • 8.4.1. Adults
  • 8.4.2. Pediatrics
• 8.5. Market Analysis, Insights and Forecast - By Distribution Channel
  • 8.5.1. Hospital Pharmacies
  • 8.5.2. Drug Stores & Retail Pharmacies
  • 8.5.3. Online Pharmacies
• 8.6. Market Analysis, Insights and Forecast - By Country/ Sub-Region
  • 8.6.1. China
  • 8.6.2. Japan
  • 8.6.3. India
  • 8.6.4. Australia
  • 8.6.5. Southeast Asia
  • 8.6.6. Rest of Asia Pacific

9. Latin America Macrolide Antibiotics Market Analysis, Insights and Forecast, 2019-2032

• 9.1. Market Analysis, Insights and Forecast - By Product
  • 9.1.1. Azithromycin
  • 9.1.2. Clarithromycin
  • 9.1.3. Oleandomycin
  • 9.1.4. Erythromycin
  • 9.1.5. Others
• 9.2. Market Analysis, Insights and Forecast - By Disease Indication
  • 9.2.1. Respiratory Infections
  • 9.2.2. Skin Infections
  • 9.2.3. Sexually Transmitted Diseases (STIs)
  • 9.2.4. Others
• 9.3. Market Analysis, Insights and Forecast - By Route of Administration
  • 9.3.1. Oral
  • 9.3.2. Parenteral
  • 9.3.3. Others
• 9.4. Market Analysis, Insights and Forecast - By Age Group
  • 9.4.1. Adults
  • 9.4.2. Pediatrics
• 9.5. Market Analysis, Insights and Forecast - By Distribution Channel
  • 9.5.1. Hospital Pharmacies
  • 9.5.2. Drug Stores & Retail Pharmacies
  • 9.5.3. Online Pharmacies
• 9.6. Market Analysis, Insights and Forecast - By Country/ Sub-Region
  • 9.6.1. Brazil
  • 9.6.2. Mexico
  • 9.6.3. Rest of Latin America

10. Middle East & Africa Macrolide Antibiotics Market Analysis, Insights and Forecast, 2019-2032

• 10.1. Market Analysis, Insights and Forecast - By Product
  • 10.1.1. Azithromycin
  • 10.1.2. Clarithromycin
  • 10.1.3. Oleandomycin
  • 10.1.4. Erythromycin
  • 10.1.5. Others
• 10.2. Market Analysis, Insights and Forecast - By Disease Indication
  • 10.2.1. Respiratory Infections
  • 10.2.2. Skin Infections
  • 10.2.3. Sexually Transmitted Diseases (STIs)
  • 10.2.4. Others
• 10.3. Market Analysis, Insights and Forecast - By Route of Administration
  • 10.3.1. Oral
  • 10.3.2. Parenteral
  • 10.3.3. Others
• 10.4. Market Analysis, Insights and Forecast - By Age Group
  • 10.4.1. Adults
  • 10.4.2. Pediatrics
• 10.5. Market Analysis, Insights and Forecast - By Distribution Channel
  • 10.5.1. Hospital Pharmacies
  • 10.5.2. Drug Stores & Retail Pharmacies
  • 10.5.3. Online Pharmacies
• 10.6. Market Analysis, Insights and Forecast - By Country/ Sub-Region
  • 10.6.1. GCC
  • 10.6.2. South Africa
  • 10.6.3. Rest of Middle East & Africa

11. Competitive Analysis

• 11.1. Global Market Share Analysis (2024)
• 11.2. Company Profiles
  • 11.2.1. Pfizer Inc.
    • 11.2.1.1. Overview
    • 11.2.1.2. Products
    • 11.2.1.3. SWOT Analysis
    • 11.2.1.4. Recent Developments
    • 11.2.1.5. Strategies
    • 11.2.1.6. Financials (Based on Availability)
  • 11.2.2. Teva Pharmaceutical Industries Ltd.
    • 11.2.2.1. Overview
    • 11.2.2.2. Products
    • 11.2.2.3. SWOT Analysis
    • 11.2.2.4. Recent Developments
    • 11.2.2.5. Strategies
    • 11.2.2.6. Financials (Based on Availability)
  • 11.2.3. Crescent Pharma Ltd.
    • 11.2.3.1. Overview
    • 11.2.3.2. Products
    • 11.2.3.3. SWOT Analysis
    • 11.2.3.4. Recent Developments
    • 11.2.3.5. Strategies
    • 11.2.3.6. Financials (Based on Availability)
  • 11.2.4. Wellona Pharma
    • 11.2.4.1. Overview
    • 11.2.4.2. Products
    • 11.2.4.3. SWOT Analysis
    • 11.2.4.4. Recent Developments
    • 11.2.4.5. Strategies
    • 11.2.4.6. Financials (Based on Availability)
  • 11.2.5. Zydus Group
    • 11.2.5.1. Overview
    • 11.2.5.2. Products
    • 11.2.5.3. SWOT Analysis
    • 11.2.5.4. Recent Developments
    • 11.2.5.5. Strategies
    • 11.2.5.6. Financials (Based on Availability)
  • 11.2.6. Merck & Co., Inc.
    • 11.2.6.1. Overview
    • 11.2.6.2. Products
    • 11.2.6.3. SWOT Analysis
    • 11.2.6.4. Recent Developments
    • 11.2.6.5. Strategies
    • 11.2.6.6. Financials (Based on Availability)
  • 11.2.7. Alkem
    • 11.2.7.1. Overview
    • 11.2.7.2. Products
    • 11.2.7.3. SWOT Analysis
    • 11.2.7.4. Recent Developments
    • 11.2.7.5. Strategies
    • 11.2.7.6. Financials (Based on Availability)
  • 11.2.8. Azurity Pharmaceuticals, Inc.
    • 11.2.8.1. Overview
    • 11.2.8.2. Products
    • 11.2.8.3. SWOT Analysis
    • 11.2.8.4. Recent Developments
    • 11.2.8.5. Strategies
    • 11.2.8.6. Financials (Based on Availability)
  • 11.2.9. Lupin
    • 11.2.9.1. Overview
    • 11.2.9.2. Products
    • 11.2.9.3. SWOT Analysis
    • 11.2.9.4. Recent Developments
    • 11.2.9.5. Strategies
    • 11.2.9.6. Financials (Based on Availability)
  • 11.2.10. Sun Pharmaceutical Industries Ltd.
    • 11.2.10.1. Overview
    • 11.2.10.2. Products
    • 11.2.10.3. SWOT Analysis
    • 11.2.10.4. Recent Developments
    • 11.2.10.5. Strategies
    • 11.2.10.6. Financials (Based on Availability)